Cover Image
市場調查報告書

Heron Therapeutics, Inc.的產品平台分析

Heron Therapeutics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321988
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
Back to Top
Heron Therapeutics, Inc.的產品平台分析 Heron Therapeutics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月31日 內容資訊: 英文 34 Pages
簡介

Heron Therapeutics, Inc.是總公司設立於美國的製藥企業。利用擁有專利的聚合物基藥物遞輸平台,以提升注射藥的治療簡介。

本報告提供Heron Therapeutics, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Heron Therapeutics, Inc.的基本資料

  • Heron Therapeutics, Inc.概要
  • 主要資訊
  • 企業資料

Heron Therapeutics, Inc.:R&D概要

  • 主要的治療範圍

Heron Therapeutics, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

Heron Therapeutics, Inc.:開發中產品概況

  • 後期階段產品開發中產品
    • 第三階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Heron Therapeutics, Inc.:藥物簡介

  • granisetron ER
  • (bupivacaine hydrochloride + meloxicam)
  • aprepitant
  • bupivacaine hydrochloride
  • ropivacaine

Heron Therapeutics, Inc.:開發平台分析

  • 標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Heron Therapeutics, Inc.:最新的開發平台資訊

Heron Therapeutics, Inc.:開發暫停中的計劃

Heron Therapeutics, Inc.:企業理念

Heron Therapeutics, Inc.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07383CDB

Summary

Global Markets Direct's, 'Heron Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Heron Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Heron Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Heron Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Heron Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Heron Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Heron Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Heron Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Heron Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Heron Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Heron Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Heron Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Heron Therapeutics, Inc. Snapshot
    • Heron Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Heron Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Heron Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Heron Therapeutics, Inc. - Pipeline Products Glance
    • Heron Therapeutics, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
    • Heron Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Heron Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Heron Therapeutics, Inc. - Drug Profiles
    • granisetron ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (bupivacaine hydrochloride + meloxicam)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • aprepitant
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bupivacaine hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • buprenorphine hydrochloride long acting
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ropivacaine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Heron Therapeutics, Inc. - Pipeline Analysis
    • Heron Therapeutics, Inc. - Pipeline Products by Target
    • Heron Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Heron Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Heron Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Heron Therapeutics, Inc. - Recent Pipeline Updates
  • Heron Therapeutics, Inc. - Dormant Projects
  • Heron Therapeutics, Inc. - Company Statement
  • Heron Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Heron Therapeutics, Inc., Key Information
  • Heron Therapeutics, Inc., Key Facts
  • Heron Therapeutics, Inc. - Pipeline by Indication, 2015
  • Heron Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Heron Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Heron Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2015
  • Heron Therapeutics, Inc. - Pre-Registration, 2015
  • Heron Therapeutics, Inc. - Phase II, 2015
  • Heron Therapeutics, Inc. - Preclinical, 2015
  • Heron Therapeutics, Inc. - Pipeline by Target, 2015
  • Heron Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Heron Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Heron Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Heron Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • Heron Therapeutics, Inc. - Dormant Developmental Projects,2015
  • Heron Therapeutics, Inc., Other Locations

List of Figures

  • Heron Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Heron Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Heron Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Heron Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Heron Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Heron Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Heron Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top